GlycoMimetics, Inc. (GKO.F)

1,4340 -0,1820 (-11,26%) Alla chiusura: 08:04AM CEST

GlycoMimetics, Inc.

9708 Medical Center Drive
Rockville, MD 20850
United States
240 243 1201
https://www.glycomimetics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 35

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Harout Semerjian	CEO, President & Director	1,05M	N/D	1970
Ms. Rachel K. King	Co-Founder & Director	37,33k	N/D	1959
Mr. Brian M. Hahn	Senior VP & CFO	767,24k	N/D	1974
Dr. Edwin Rock M.D., Ph.D.	Senior VP & Chief Medical Officer	632,18k	N/D	1961
Ms. Stephanie R. Irish CPA	Vice President of Accounting	N/D	N/D	1971
Mr. Christian B. Dinneen-Long	General Counsel & Company Secretary	N/D	N/D	N/D
Mr. Bruce Johnson	Senior VP & Chief Commercial Officer	N/D	N/D	1968
Mr. Chinmaya Rath	Senior VP & Chief Business Officer	N/D	N/D	1977
Mr. Shantha Tyavanagimatt Ph.D.	Senior Vice President of Technical Operations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Governance aziendale

L'ISS Governance QualityScore di GlycoMimetics, Inc. al 29 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.